SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer therapies, including the WT1 cancer vaccine poised to enter pivotal Phase 3 clinical testing in 1Q 2016 and the earlier stage TR1 technology to enter Phase 1 clinical trial by 2H 2016. SELLAS is also developing high-dose Zolpidem for diseases of the central nervous system (CNS), with a Phase 2b clinical trial expected to commence in the first half of next year.
SELLAS focuses on in-licensing drug candidates that are undergoing or have already completed initial (pre-) clinical testing and then seeks to further develop those drug candidates for commercial use. The Company's management team has a proven track record of developing drugs and cancer vaccines throughout all stages of the product's life cycle, and the team has played key roles in bringing companies public, successfully out-licensing drug candidates, forming R&D partnerships with big pharma, and creating multiple alliances with centers of excellence.SELLAS Life Sciences Group to Present at J.P. Morgan Healthcare Conference in January
Dr. Angelos M. Stergiou, President and Chief Executive Officer of SELLAS, will make a formal presentation on the company at the 34th Annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis Hotel in San Francisco, CA. The presentation will take place on January 12th, 2016, at 3:30pm pacific.